AKT1 and breast cancer: PI3K pathway biomarkers status in primary BC and their matched BCBM was concordant in 67%, 58%, and 83% of 12 cases for p-AKT, p-S6, and PTEN, respectively (Table 3), and both gains and losses of which were evident for each biomarker evaluated.